Need Help?

Prospective high-throughput genome profiling in advanced cancers:

Genomics-based tumor profiling in advanced cancers (aC) was recently demonstrated as feasible in clinical practice. After the prospective pilot PANDORA study done on advanced breast cancers, we conducted a prospective monocenter clinical trial called PERMED01 to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples could lead to the delivery of a targeted therapy

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006289 Illumina MiSeq NextSeq 500 735
Publications Citations
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Genome Med 13: 2021 87
BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.
Cell Death Dis 13: 2022 96
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
Cancers (Basel) 14: 2022 2275